Skip to main content

Advertisement

Table 3 Comparisons of cerebrospinal fluid soluble TREM2 levels between all disease groups and subgroups and controls

From: Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup

Groups compared Mean (SEM) difference in CSF sTREM2 (ng/ml) 95% CI for CSF sTREM2 (ng/ml) P value
Dementia vs. control 0.638 (0.806) −0.966, 2.244 0.431
Clinical subgroups
 bvFTD vs. control −0.349 (1.035) −2.413, 1.713 0.736
 nfvPPA vs. control 0.544 (1.009) −1.468, 2.556 0.592
 svPPA vs. control 1.145 (1.129) −1.107, 3.397 0.314
 lvPPA vs. control 1.040 (1.037) −1.025, 3.106 0.319
 PPA-NOS vs. control 1.840 (1.837) −1.820, 5.502 0.320
 nfvPPA vs. bvFTD 0.305 (1.153) −2.004, 2.615 0.792
 svPPA vs. bvFTD 1.344 (1.190) −1.041, 3.729 0.264
 lvPPA vs. bvFTD 0.723 (1.224) −1.730, 3.176 0.557
 PPA-NOS vs. bvFTD 1.228 (1.927) −2.631, 5.088 0.526
 svPPA vs. nfvPPA 1.038 (1.247) −1.460, 3.537 0.409
 lvPPA vs. nfvPPA 0.417 (1.101) −1.789, 2.624 0.706
 PPA-NOS vs. nfvPPA 0.922 (1.939) −2.961, 4.806 0.636
 lvPPA vs. svPPA −0.621 (1.287) −3.199, 1.957 0.631
 PPA-NOS vs. svPPA −0.116 (2.016) −4.154, 3.923 0.954
 PPA-NOS vs. lvPPA 0.505 (1.967) −3.343, 4.445 0.798
Genetic subgroups
GRN vs. control 2.748 (1.161) 0.331, 5.163 0.028a
MAPT vs. control −2.230 (1.144) −4.609, 0.149 0.065
C9orf72 vs. control −1.897 (1.266) −4.529, 0.735 0.149
GRN vs. MAPT 4.978 (1.483) 1.893, 8.063 0.003a
GRN vs. C9orf72 4.644 (1.536) 1.448, 7.840 0.006a
C9orf72 vs. MAPT 0.334 (1.408) −2.595, 3.262 0.815
Pathological subgroups
 AD biomarker-positive dementia vs. controls 1.921 (0.996) −0.062, 3.905 0.057
 AD biomarker-negative dementia vs. controls 0.183 (0.817) −1.446, 1.812 0.823
 AD biomarker-positive dementia vs. AD biomarker-negative dementia F(2,58) = 3.77, P = 0.029a,b
  1. See list of abbreviations for definition of abbreviations
  2. Mean differences and 95% CIs are β values arising from multivariable linear regressions, adjusted for age and sex (disease groups and subgroups vs. controls), or age, sex and disease duration (between disease groups or subgroups, except for between genetic subgroups, which were adjusted for age and sex). Dementia group includes all individuals with FTD (bvFTD and PPA)
  3. aSignificant at P < 0.05
  4. bDifference between groups changes with varying disease duration; results of regression analysis comparing groups overall are presented, rather than specific value for mean difference